| 1. |
New targets for anxiolytics |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Management guidelines for onychomycosis have been prepared for dermatologists on behalf of the British Association of Dermatologists. |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
The endpoints used by the US FDA to approve new oncology drug applications have been summarised, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Savings of nearly $US1.5 million have been realised by CHA Health in the first 2 years of a cancer disease management (DM) programme |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
A combination of TA-CIN*and TA-HPV*candidate vaccines demonstrated clear responses |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Ximelagatran reduces stroke risk in atrial fibrillation |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 7-8
RM Poole,
Preview
|
|
摘要:
The oral direct thrombin inhibitor ximelagatran ['Exanta'] offers significant advantages over warfarin for the prevention of stroke in patients with atrial fibrillation, according to results from the SPORTIF III study presented at the 52nd Annual Meeting and Scientific Sessions of the American College of Cardiology [Chicago, US; March−April 2003]. This study, part of the SPORTIF clinical trial programme, showed that ximelagatran reduced the incidence of stroke and systemic embolic events in patients with atrial fibrillation, and was associated with a reduced risk of bleeding, compared with warfarin. Furthermore, unlike warfarin, ximelagatran could be administered as a fixed oral dose without titration or coagulation monitoring.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Oculex Pharmaceuticals has announced positive clinical results for its ocular implant 'Posurdex' |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
Genentech and XOMA have decided to discontinue testing efalizumab ['Raptiva'] in rheumatoid arthritis, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Insulin gene transfer enhances human islet graft function |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Galantamine: dual mechanism advantageous in dementia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1387,
2003,
Page 11-12
RM Poole,
Preview
|
|
摘要:
Galantamine ['Reminyl'] may be more effective than donepezil ['Aricept'] in the treatment of moderate-to-severe Alzheimer's disease, according to a study presented at the 55th Annual Meeting of the American Academy of Neurology [Honolulu, US; March-April 2003]. Cognition, particularly attention, and caregiver burden were significantly improved in galantamine, compared with donepezil, recipients in this 52-week study. Another study presented at the meeting showed that galantamine was suitable for long-term use in the treatment of Alzheimer's disease and vascular dementia. Finally, results from a small open-label study suggested that galantamine may also be effective in the treatment of Lewy body disease, a major cause of dementia in elderly patients.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
